Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F19%3AN0000019" target="_blank" >RIV/00023728:_____/19:N0000019 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/19:10404484

Výsledek na webu

<a href="https://doi.org/10.12688/f1000research.18688.1" target="_blank" >https://doi.org/10.12688/f1000research.18688.1</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.12688/f1000research.18688.1" target="_blank" >10.12688/f1000research.18688.1</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies

Popis výsledku v původním jazyce

Idiopathic inflammatory myopathies (IIM) belong to a group of autoimmune disorders, primarily characterized by chronic inflammation of human skeletal muscle tissue. The etiology of these diseases is unknown, however, genetic predisposition plays a significant role in disease onset. Beside the known genetic risk located in the MHC complex, the epigenetic modifications including changes in miRNAs expression profiles have been recently implicated recently in many autoimmune diseases. Micro RNA molecules are involved in many physiological processes, including the regulation of the immune response. In our study we have focused on the miR-23b, as it represents a novel promising autoimmunity regulator molecule. Downregulation of miR-23b was recently described in patients with rheumatoid arthritis and systemic lupus erythematosus. We have measured the expression miR-23b peripheral blood mononuclear cells of patients with dermatomyositis and polymyositis. No meaningful difference was found in comparison with healthy controls.

Název v anglickém jazyce

Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies

Popis výsledku anglicky

Idiopathic inflammatory myopathies (IIM) belong to a group of autoimmune disorders, primarily characterized by chronic inflammation of human skeletal muscle tissue. The etiology of these diseases is unknown, however, genetic predisposition plays a significant role in disease onset. Beside the known genetic risk located in the MHC complex, the epigenetic modifications including changes in miRNAs expression profiles have been recently implicated recently in many autoimmune diseases. Micro RNA molecules are involved in many physiological processes, including the regulation of the immune response. In our study we have focused on the miR-23b, as it represents a novel promising autoimmunity regulator molecule. Downregulation of miR-23b was recently described in patients with rheumatoid arthritis and systemic lupus erythematosus. We have measured the expression miR-23b peripheral blood mononuclear cells of patients with dermatomyositis and polymyositis. No meaningful difference was found in comparison with healthy controls.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30226 - Rheumatology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

F1000Research

ISSN

2046-1402

e-ISSN

2046-1402

Svazek periodika

8

Číslo periodika v rámci svazku

Nr.1549

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

12

Strana od-do

1-12

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85072020266